INTERNATIONAL PATENT: NOVIMMUNE SA FILES APPLICATION FOR "COMBINATION THERAPY WITH A CEA X CD28 BISPECIFIC ANTIBODY AND BLOCKING ANTI-PD-1 ANTIBODIES FOR ENHANCED IN VIVO ANTI-TUMOR ACTIVITY"

GENEVA, March 17 -- NOVIMMUNE SA (Chemin du Pre-Fleuri 15Plan-Les-Ouates1228 Geneva) filed a patent application (PCT/EP2024/074894) for "COMBINATION THERAPY WITH A CEA X CD28 BISPECIFIC ANTIBODY AND BLOCKING ANTI-PD-1 ANTIBODIES FOR ENHANCED IN VIVO ANTI-TUMOR ACTIVITY" on Sep 05, 2024. With publication no. WO/2025/051895, the details related to the patent application was published on Mar 13, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): MAJOCCHI, Sara (c/o Novimmune SAChemin du Pre-Fleuri 15Plan-Les-Ouates1228 Geneva), SHANG, Limin (c/o Novimmune SAChemin du Pre-Fleuri 15Plan-Les-Ouates12...